APremilast After FumaRic Acid Ester Treatment

Apremilast in Palmo-Plantar Psoriasis

NCT02400749 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

NCT06586112 ·Status: COMPLETED ·Phase: PHASE3

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

NCT03721172 ·Status: COMPLETED ·Phase: PHASE3

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299 ·Status: COMPLETED ·Phase: PHASE3

A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

NCT02576678 ·Status: COMPLETED ·Phase: PHASE2

Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions

NCT03106051 ·Status: COMPLETED

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

NCT01988103 ·Status: COMPLETED ·Phase: PHASE2

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03611751 ·Status: COMPLETED ·Phase: PHASE3

The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis

NCT01088165 ·Status: UNKNOWN ·Phase: PHASE4

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

NCT00521339 ·Status: COMPLETED ·Phase: PHASE2

Observational Study of Apremilast in Patients With Psoriasis in The Netherlands

NCT02652494 ·Status: COMPLETED

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475 ·Status: COMPLETED ·Phase: PHASE4

Mechanism of Action Study for Psoriasis

NCT00932113 ·Status: COMPLETED ·Phase: PHASE4

A Phase III Study in Subjects With Mild to Moderate Psoriasis.

NCT05249972 ·Status: UNKNOWN ·Phase: PHASE3

Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）

NCT05863273 ·Status: COMPLETED

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

NCT03624127 ·Status: COMPLETED ·Phase: PHASE3

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

NCT06122649 ·Status: COMPLETED ·Phase: PHASE3

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

NCT06588738 ·Status: COMPLETED ·Phase: PHASE3

Treatment With Apremilast in Patients With Psoriatic Arthritis

NCT02558361 ·Status: WITHDRAWN ·Phase: PHASE4

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02850965 ·Status: COMPLETED ·Phase: PHASE3

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

NCT05073315 ·Status: COMPLETED ·Phase: PHASE3

Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

NCT01812954 ·Status: COMPLETED

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment

NCT02634801 ·Status: COMPLETED ·Phase: PHASE3

Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

NCT02412644 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy

NCT04263610 ·Status: COMPLETED ·Phase: PHASE4